PT-141

evidence score

peptide

Prescription Only

169 studies

bremelanotideVyleesiPT141

PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist sold as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally on the hypothalamus rather than on vascular smooth muscle. Off-label use by men for erectile dysfunction and libido enhancement is common. It produces sexual arousal and desire independent of physical stimulation via MC3R and MC4R agonism. Works within 45 minutes; effects last 6–12 hours.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

Approved

Research Sync

Feb 19, 2026

Dosing

Typical

1.75 mg

0.75 mgRange2 mg

FrequencyAs needed, maximum 1x/24 hours, 8x/month

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~2.7 hours

Onset45 minutes to 1 hour

Duration6–12 hours

Routes

subcutaneous

Evidence Score

Level B — Moderate

169 studies indexed · 3 meta-analyses

Scoring Factors

Volume(40%)~45/100

Quality(30%)~48/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

PT-141 is currently categorized as a peptide compound.

Evidence is moderate (71/100): promising signal from 169 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

MC3R and MC4R agonist in the hypothalamus; activates central arousal pathways independent of vascular mechanisms

Practical Context

Strongest current signals

Level A: Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Level C: Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.
Level C: Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.